Trial Profile
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2011
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 04 Apr 2011 New trial record